The role of infections in the pathogenesis and course of multiple sclerosis

Annals of Indian Academy of Neurology

Volumn 13, Issue 2, 2010, Pages 80-86

  Pawate, Siddharama ^a   Sriram, Subramaniam ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

cellular immunity; molecular mimicry; oligoclonal bands; Oligodendrocyte; toll like receptors

Indexed keywords

IMMUNOGLOBULIN; MYELIN ASSOCIATED GLYCOPROTEIN;

ANTIGEN PRESENTING CELL; CEREBROSPINAL FLUID; CHLAMYDOPHILA PNEUMONIAE; DEMYELINATION; DISEASE MODEL; EPSTEIN BARR VIRUS; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN HERPESVIRUS 6; MULTIPLE SCLEROSIS; NONHUMAN; OLIGODENDROGLIA; PREVALENCE; RELAPSE; RETROVIRUS; REVIEW; VIRUS INFECTION;

EID: 77954222516     PISSN: 09722327     EISSN: 19983549     Source Type: Journal    
DOI: 10.4103/0972-2327.64622     Document Type: Review

References (85)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372: 1502-1517
2. Sriram S, Steiner I. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann Neurol 2005;58: 939-945
3. Mayr WT, Pittock SJ, McClelland RL, Jorgensen NW, Noseworthy JH, Rodriguez M. Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000. Neurology 2003;61:1373-1377
4. Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vécsei L, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006;13:700-722
5. Orton SM, Herrera BM, Yee IM, Valdar W, Ramagopalan SV, Sadovnick AD, et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 2006;5:932-936
6. Singhal BS. Multiple sclerosis-Indian experience. Ann Acad Med Singapore 1985;14:32-36
7. Gangopadhyay G, Das SK, Sarda P, Saha SP, Gangopadhyay PK, Roy TN, et al. Clinical profile of multiple sclerosis in Bengal. Neurol India 1999;47:18-21
8. Mani J, Chaudhary N, Ravat S, Shah PU. Multiple sclerosis: experience in neuroimaging era from western India. Neurol India 1999;47:8-11
9. Frohman EM, Filippi M, Stuve O, Waxman SG, Corboy J, Phillips JT, et al. Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. Arch Neurol 2005;62:1345-1356
10. Benedict RH, Bobholz JH. Multiple sclerosis. Semin Neurol 2007;27:78-85
11. Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 2006;5:343-354
12. Miller DH, Leary SM., Primary-progressive multiple sclerosis. Lancet Neurol 2007;6:903-912
13. Vukusic S, Confavreux C. Primary and secondary progressive multiple sclerosis. J Neurol Sci 2003;206:153-155
14. Compston A, Coles A. Multiple sclerosis. Lancet 2002;359: 1221-1231
15. Frohman EM, Racke MK, Raine CS. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 2006;354:942-955
16. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-717
17. Bö L, Geurts JJ, Mörk SJ, van der Valk P. Grey matter pathology in multiple sclerosis. Acta Neurol Scand Suppl 2006;183:48-50
18. Kutzelnigg A, Lassmann H. Cortical demyelination in multiple sclerosis: a substrate for cognitive deficits? J Neurol Sci 2006;245:123-126
19. Kornek B, Lassmann H. Neuropathology of multiple sclerosis-new concepts. Brain Res Bull 2003;61:321-326
20. Peterson JW, Trapp BD. Neuropathobiology of multiple sclerosis. Neurol Clin 2005;23:107-129
21. Baringer JR. Herpes simplex infections of the nervous system. Neurol Clin 2008;26:657-674
22. Estanislao LB, Pachner AR. Spirochetal infection of the nervous system. Neurol Clin 1999;17:783-800
23. Panegyres PK, Edis R, Beaman M, Fallon M. Primary Whipple's disease of the brain: characterization of the clinical syndrome and molecular diagnosis. QJM 2006;99:609-623
24. Weber T. Progressive multifocal leukoencephalopathy. Neurol Clin 2008;26:833-854
25. Verdonck K, González E, Van Dooren S, Vandamme AM, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis 2007;7:266-281
26. Oleszak EL, Chang JR, Friedman H, Katsetos CD, Platsoucas CD. Theiler's virus infection: a model for multiple sclerosis. Clin Microbiol Rev 2004;17:174-207
27. Ebers GC, Sadovnick AD. The geographic distribution of multiple sclerosis: a review. Neuroepidemiology 1993;12:1-5
28. Poser CM. The dissemination of multiple sclerosis: a Viking saga? A historical essay. Ann Neurol 1994;36:231-243
29. Hammond SR, McLeod JG, Millingen KS, Stewart-Wynne EG, English D, Holland JT, et al. The epidemiology of multiple sclerosis in three Australian cities: Perth, Newcastle and Hobart. Brain 1988;111:1-25
30. Kurtzke JF, Delasnerie-Lauprêtre N, Wallin MT. Multiple sclerosis in North African migrants to France. Acta Neurol Scand 1998;98:302-309
31. Hammond SR, English DR, McLeod JG. The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia. Brain 2000;123:968-974
32. Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol 2008;7:268-277
33. Kurtzke JF, Heltberg A. Multiple sclerosis in the Faroe Islands: an epitome. J Clin Epidemiol 2001;54:1-22
34. Kurtzke JF, Gudmundsson KR, Bergmann S. Multiple sclerosis in Iceland: 1. Evidence of a postwar epidemic. Neurology 1982;2:143-150
35. Kurtzke JF. Multiple sclerosis in time and space-geographic clues to cause. J Neurovirol 2000;6:134-140
36. Poser CM, Hibberd PL, Benedikz J, Gudmundsson G. Analysis of the 'epidemic' of multiple sclerosis in the Faroe Islands. I. Clinical and epidemiological aspects. Neuroepidemiology 1988;7:168-180
37. Poser CM. The epidemiology of multiple sclerosis: a general overview. Ann Neurol 1994;36:180-193
38. Kurtzke JF. Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev 1993;6:382-427
39. Poskanzer DC, Walker AM, Yonkondy J, Sheridan JL. Studies in the epidemiology of multiple sclerosis in the Orkney and Shetland Islands. Neurology 1976;26:14-17
40. Leibowitz U, Antonovsky A, Medalie JM, Smith HA, Halpern L, Alter M. Epidemiological study of multiple sclerosis in Israel. II. Multiple sclerosis and level of sanitation. J Neurol Neurosurg Psychiatry 1966;29:60-68
41. Luque FA, Jaffe SL. Cerebrospinal fluid analysis in multiple sclerosis. Int Rev Neurobiol 2007;79:341-356
42. Link H, Cruz M, Gessain A, Gout O, de Thé G, Kam-Hansen S. Chronic progressive myelopathy associated with HTLV-I: oligoclonal IgG and anti-HTLV-I IgG antibodies in cerebrospinal fluid and serum. Neurology 1989;39:1566-1572
43. Vartdal F, Vandvik B, Michaelsen TE, Loe K, Norrby E. Neurosyphilis: intrathecal synthesis of oligoclonal antibodies to Treponema pallidum. Ann Neurol 1982;11:35-40
44. Wang ZY, Hansen K, Sidén A, Cruz M. Intrathecal synthesis of anti-Borrelia burgdorferi antibodies in neuroborreliosis: a study with special emphasis on oligoclonal IgM antibody bands. Scand J Immunol 1993;37:369-376
45. Scott TF, Seay AR, Goust JM. Pattern and concentration of IgG in cerebrospinal fluid in neurosarcoidosis. Neurology 1989;39: 1637-1639
46. Sriram S, Stratton CW, Yao S, Tharp A, Ding L, Bannan JD, et al. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann Neurol 1999;46:6-14
47. Felts PA, Woolston AM, Fernando HB, Asquith S, Gregson NA, Mizzi OJ, et al. Inflammation and primary demyelination induced by the intraspinal injection of lipopolysaccharide. Brain 2005;128:1649-1666
48. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004;55:458-468
49. Marik C, Felts PA, Bauer J, Lassmann H, Smith KJ. Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain 2007;130:2800-2815
50. Fujinami RS, von Herrath MG, Christen U, Whitton JL. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev 2006;19:80-94
51. Watson C, Alp NJ. Role of Chlamydia pneumoniae in atherosclerosis. Clin Sci 2008;114:509-531
52. Yucesan C, Sriram S. Chlamydia pneumoniae infection of the central nervous system. Curr Opin Neurol 2001;14:355-359
53. Sriram S, Mitchell W, Stratton C. Multiple sclerosis associated with Chlamydia pneumoniae infection of the CNS. Neurology 1998;50:571-572
54. Boman J, Roblin PM, Sundström P, Sandström M, Hammerschlag MR. Failure to detect Chlamydia pneumoniae in the central nervous system of patients with MS. Neurology 2000;54:265
55. Numazaki K, Chibar S. Failure to detect Chlamydia pneumoniae in the central nervous system of patients with MS. Neurology 2001;57:746
56. Kaufman M, Gaydos CA, Sriram S, Boman J, Tondella ML, Norton HJ. Is Chlamydia pneumoniae found in spinal fluid samples from multiple sclerosis patients? Conflicting results. Mult Scler 2002;8:289-294
57. Bagos PG, Nikolopoulos G, Ioannidis A. Chlamydia pneumoniae infection and the risk of multiple sclerosis: a meta-analysis. Mult Scler 2006;12:397-411
58. Dockrell DH, Smith TF, Paya CV. Human herpesvirus 6. Mayo Clin Proc 1999;74:163-170
59. Moore FG, Wolfson C. Human herpes virus 6 and multiple sclerosis. Acta Neurol Scand 2002;106:63-83 (Pubitemid 34831922)
60. Hall CB, Long CE, Schnabel KC, Caserta MT, McIntyre KM, Costanzo MA, Knott A, et al. Human herpesvirus-6 infection in children. A prospective study of complications and reactivation. N Engl J Med 1994;331:432-438
61. Challoner PB, Smith KT, Parker JD, MacLeod DL, Coulter SN, Rose TM, et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci U S A 1995;92:7440-7444
62. Soldan SS, Berti R, Salem N, Secchiero P, Flamand L, Calabresi PA, et al. Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nat Med 1997;3:1394-1397
63. Cermelli C, Berti R, Soldan SS, Mayne M, D'ambrosia JM, Ludwin SK, et al. High frequency of human herpesvirus 6 DNA in multiple sclerosis plaques isolated by laser microdissection. J Infect Dis 2003;187:1377-1387
64. Mirandola P, Stefan A, Brambilla E, Campadelli-Fiume G, Grimaldi LM. Absence of human herpesvirus 6 and 7 from spinal fluid and serum of multiple sclerosis patients. Neurology 1999;53:1367-1368
65. Xu Y, Linde A, Fredrikson S, Dahl H, Winberg G. HHV-6 A- or B-specific P41 antigens do not reveal virus variant-specific IgG or IgM responses in human serum. J Med Virol 2002;66:394-399
66. Liedtke W, Malessa R, Faustmann PM, Eis-Hübinger AM. Human herpesvirus 6 polymerase chain reaction findings in human immunodeficiency virus associated neurological disease and multiple sclerosis. J Neurovirol 1995;1:253-258
67. Junker AK. Epstein-Barr virus. Pediatr Rev 2005;26:79-85
68. Barzilai O, Sherer Y, Ram M, Izhaky D, Anaya JM, Shoenfeld Y. Epstein-Barr virus and cytomegalovirus in autoimmune diseases: are they truly notorious? A preliminary report. Ann N Y Acad Sci 2007;1108:567-577
69. Wandinger K, Jabs W, Siekhaus A, Bubel S, Trillenberg P, Wagner H, et al. Association between clinical disease activity and Epstein- Barr virus reactivation in MS. Neurology 2000;55:178-184
70. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 2007;61:288-299 (Pubitemid 46676728)
71. Hilton DA, Love S, Fletcher A, Pringle JH. Absence of Epstein-Barr virus RNA in multiple sclerosis as assessed by in situ hybridisation. J Neurol Neurosurg Psychiatry 1994;57:975-976
72. Jilek S, Schluep M, Meylan P, Vingerhoets F, Guignard L, Monney A, et al. Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Brain 2008;131:1712-1721
73. Zivadinov R. Epstein-Barr Virus is Associated with Gray Matter Atrophy in Multiple Sclerosis. J Neurol Neuro Psy 2009
74. Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007;204:2899-2912
75. Christensen T. Association of human endogenous retroviruses with multiple sclerosis and possible interactions with herpes viruses. Rev Med Virol 2005;15:179-211
76. Clausen J. Endogenous retroviruses and MS: using ERVs as disease markers. Int MS J 2003;10:22-28
77. Perron H, Garson JA, Bedin F, Beseme F, Paranhos-Baccala G, Komurian-Pradel F, et al. Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. The Collaborative Research Group on Multiple Sclerosis. Proc Natl Acad Sci U S A 1997;94:7583-7588
78. Dessau RB, Lisby G, Frederiksen JL. Coronaviruses in brain tissue from patients with multiple sclerosis. Acta Neuropathol 2001;101:601-604
79. Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985;1:1313-1315
80. Andersen O, Lygner PE, Bergström T, Andersson M, Vahlne A. Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study. J Neurol 1993;240:417-422
81. Rapp NS, Gilroy J, Lerner AM. Role of bacterial infection in exacerbation of multiple sclerosis. Am J Phys Med Rehabil 1995;74:415-418
82. Buljevac D, Flach HZ, Hop WC, Hijdra D, Laman JD, Savelkoul HF, et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 2002;125:952-960
83. Correale J, Fiol M, Gilmore W. The risk of relapses in multiple sclerosis during systemic infections. Neurology 2006;67:652-659
84. Konturek SJ, Konturek PC, Konturek JW, Plonka M, Czesnikiewicz- Guzik M, Brzozowski T, et al. Helicobacter pylori and its involvement in gastritis and peptic ulcer formation. J Physiol Pharmacol 2006;57:29-50
85. Lipton HL, Liang Z, Hertzler S, Son KN. A specific viral cause of multiple sclerosis: one virus, one disease. Ann Neurol 2007;61:514-523